Evidence Base for MEDIHONEY(TM) Dressings Growing
PRINCETON, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that four abstracts detailing the clinical usage of its newly released MEDIHONEY(TM) Wound & Burn Dressings with Active Leptospermum Honey were accepted for presentation at the upcoming annual American Professional Wound Care Association conference, held this year between March 6 - 9 in Forth Worth, Texas. Additionally, the company has announced that the use of MEDIHONEY(TM) Dressings is a topic on the general session agenda for the conference.
About the product's recognition at the upcoming conference, CEO Edward Quilty said, "The fact that so many abstracts were developed and accepted at a national conference after only four months on the market speaks volumes to the effectiveness of the MEDIHONEY(TM) dressings. Based on the response and clinical evidence generated while on the market in Europe over the past two years, we had a good sense of what would happen upon our launch in the US and Canada. It is exciting to see the product meeting our very high expectations, and to know that we are contributing to the well-being of many patients who would otherwise have very few options."
The abstracts include the following:
"Chronic Lower Extremity Ulceration -- Use of a Leptospermum Impregnated Alginate to Accelerate Wound Closure", Dr. Matt Regulski, DPM, Toms River Foot and Ankle Surgical Associates, New Jersey.
"Clinical Application of Absorbent Calcium Alginate Dressing Pads, Containing Manuka (Leptospermum) Honey, in Infected Lower Extremity Venous Ulcers", Dr. Paul Kesselman, DPM, Brooklyn, NY
"Favorable Treatment Outcomes of Chronic Leg Ulcers with the Use of a
New Leptospermum Honey Alginate Dressing", Dr. Paul A. Ligouri, MD and Kim
L. Peters, RN, CWS, Whittier Rehabilitation Hospital, Haverhill, MA.
|SOURCE Derma Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved